Table 1.

Demographic characteristics of COVID-19 positive cancer patients.

	Total (n = 156)		WHO COVID grade
			Mild/moderate (n = 128)		Severe (n = 28)
	n	%	n	%	n	%
Sex
Male	90	57.70	71	55.50	19	67.90
Female	66	42.30	57	44.50	9	32.10
Age
<50	21	13.50	16	12.50	5	17.90
50–59	29	18.60	24	18.80	5	17.90
60–69	43	27.60	35	27.30	8	28.60
70–79	35	22.40	28	21.90	7	25.00
≥80	28	17.90	25	19.50	3	10.70
Mean (SD)	65.18 (14.80)		65.74 (14.39)		62.62 (16.41)
SES
Low	126	80.80	106	82.80	20	71.40
Medium	1	0.60	1	0.80	0	0.00
High	16	10.30	12	9.40	4	14
Missing	13	8.30	9	7.00	4	14.30
Ethnicity
White British	66	42.30	50	39.10	16	57.10
White other	12	7.70	9	7.00	3	10.70
Black Caribbean	8	5.10	8	6.30	0	0.00
Black African	15	9.60	14	10.90	1	3.60
Black other	12	7.70	9	7.00	3	10.70
Asian	6	3.80	4	3.10	2	7.10
Mixed	2	1.30	2	1.60	0	0.00
Other	5	3.20	4	3.10	1	3.60
Unknown	30	19.20	28	21.90	2	7.10
Comorbidities
Hypertension	74	47.40	63	49.20	11	39.30
Diabetes mellitus	35	22.40	31	24.20	4	14.30
Lung conditions	25	16.00	17	13.30	8	28.60
Renal impairment	30	19.20	26	20.30	4	14.30
Liver conditions	3	1.90	3	2.30	0	0.00
CVD	29	18.60	24	18.80	5	17.90
Frailty	10	6.40	6	4.70	4	14.30
Chronic steroid use	4	2.60	4	3.10	0	0.00
No. of comorbidities
0	43	27.60	34	26.60	9	32.10
1	48	30.80	40	31.30	8	28.60
2	33	21.20	28	21.90	5	17.90
3+	32	20.50	26	20.30	6	21.40
Smoking history
Never	59	37.80	51	39.80	8	28.60
Current	11	7.10	9	7.00	2	7.10
Ex-smoker	39	25.00	31	24.20	8	28.60
Unknown	47	30.10	37	28.90	10	35.70
Medications
Polypharmacy	68	43.60	57	44.50	11	39.30
NSAIDs	20	12.80	16	12.50	4	14.30
ACE/ARB	33	21.20	29	22.70	4	14.30
Beta-blockers	24	15.40	20	15.60	4	14.30